A Phase 1b Study Of The 4-1bb Agonist Pf-05082566 In Combination With The Pd-1 Inhibitor Mk-3475 In Patients With Advanced Solid Tumors

Trial Profile

A Phase 1b Study Of The 4-1bb Agonist Pf-05082566 In Combination With The Pd-1 Inhibitor Mk-3475 In Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Utomilumab (Primary)
  • Indications Colon cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Thymoma; Thyroid cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-0036
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2017 Planned number of patients changed from 23 to 45.
    • 23 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top